AcelRx Pharmaceuticals Inc neurology news

AcelRx will reduce headcount by 19 (36%) to focus resources on seeking FDA approval of Zalviso sufentanil sublingual tablet system and on development of ARX-04. The cuts primarily affect the commercial team and field-based medical personnel, who were hired in preparation for a potential launch of Zalviso. The company expects the workforce cuts to save about $900,000 per quarter. Additionally, the company appointed Howard Rosen, a director, as interim CEO, effective April 1. He will succeed Richard King. At Dec. 31, 2014, AcelRx had $75.4 million in cash and a 2014 operating loss of $37.7 million. ...